Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 4/20 | 0.49 |
| ▸ | CTSL | P07711 | 4/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6771272 | 1.00 | CTSV (0.49) | CTSVCTSLCYP19A1BACE1APP | |
| SCHEMBL6772371 | 0.89 | CTSV (0.50) | CTSVCTSLBACE1APPKDM4E | |
| SCHEMBL6772382 | 0.89 | CTSV (0.50) | CTSVCTSLBACE1APPKDM4E | |
| SCHEMBL6770462 | 0.86 | APP (0.49) | CTSLBACE1APPBRD4KDM4E | |
| SCHEMBL6770468 | 0.86 | APP (0.49) | CTSLBACE1APPBRD4KDM4E | |
| SCHEMBL6777958 | 0.84 | CYSLTR2 (0.50) | CTSVCTSLBACE1APPKDM4E | |
| SCHEMBL6777964 | 0.84 | CYSLTR2 (0.50) | CTSVCTSLBACE1APPKDM4E | |
| SCHEMBL6770154 | 0.82 | BACE1 (0.48) | BACE1APPKDM4EALDH1A1HPGD | |
| SCHEMBL6770151 | 0.82 | BACE1 (0.48) | BACE1APPKDM4EALDH1A1HPGD | |
| SCHEMBL16076970 | 0.81 | CTSV (0.56) | CTSVCTSLBACE1APPKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683095-B2 | ANTICARCINOGENIC AGENTS; ANTIPROLIFERATION AGENTS | LG LIFE SCIENCES LTD. (KR) | 2004-01-27 | — | — | US | disclosed |
| US-20030125356-A1 | Cdk inhibitors having 3-hydroxychromen-4-one structure | LG LIFE SCIENCES LTD. (KR) | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125356-A1 | Cdk inhibitors having 3-hydroxychromen-4-one structure | CDK4, CDK3, CDK6 | CTSV 3277/4885CTSL 3005/4885CYP19A1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.